Acacia Research Corporation — Q3 2016 Form 10-Q
Reporting period: Three and nine months ended September 30, 2016. Acacia’s subsidiaries invest in, license and enforce patent rights; revenue is generally recognized from license agreements, often one-time, paid-up fees.
Financial performance and position
Amounts below are in millions except per-share data. Margin figures are approximate calculations from reported amounts.
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $64.7 | $13.0 | $130.7 | $87.5 |
| Operating income (loss) | $16.3 | $(26.8) | $(28.4) | $(39.4) |
| Operating margin | 25.2% | (206.5)% | (21.7)% | (45.1)% |
| Net income (loss) attributable to Acacia | $7.1 | $(27.3) | $(43.5) | $(44.1) |
| Basic and diluted EPS | $0.14 | $(0.55) | $(0.87) | $(0.90) |
| Operating cash flow | Not presented quarterly | $23.2 | $2.2 |
Q3 revenue rose 398%, primarily because average revenue per agreement increased to $5.9 million from $1.6 million; Acacia signed 11 agreements versus 8. Nine-month revenue rose 49%, despite 30 agreements versus 51, for the same primary reason. Q3 operating income turned positive; the nine-month loss narrowed, but included a $40.2 million patent-asset impairment, primarily the write-off of the remaining Adaptix portfolio carrying value. Q3 net income included $9.7 million of income tax expense; the nine-month effective tax rate was 56%, primarily reflecting foreign withholding taxes.
At September 30, cash and cash equivalents were $116.0 million, restricted cash $14.0 million, and short-term investments $30.3 million. Cash, cash equivalents and investments excluding restricted cash totaled $146.3 million. Current assets were $218.1 million and current liabilities $47.9 million; working capital including restricted cash was $170.1 million. Acacia reported no long-term debt. Accounts receivable were $53.7 million, up from $33.5 million at year-end 2015. Management said most receivables were collected or scheduled for collection in Q4 2016.
Material changes and capital allocation
- Patent amortization declined to $28.0 million for the nine months from $40.0 million, partly due to earlier impairment charges. Patent litigation and licensing expense also declined to $22.4 million from $28.0 million.
- Nine-month operating cash flow improved to $23.2 million. Investing used $41.3 million, including patent investments, purchases of investments and the Veritone transaction; financing used $1.1 million. Cash and cash equivalents fell $19.2 million from year-end, while short-term investments increased.
- Acacia ended its dividend policy in February 2016; it paid no dividends in the nine months, compared with $19.1 million in the prior-year period.
- Patent portfolio intake remained limited: two portfolios were added in the first nine months. Management cited a strategic emphasis on quality and industry/legal challenges to acquiring portfolios.
Outlook, risks and unusual items
- Management said cash and anticipated operating cash flows should meet requirements through at least November 2017. No specific revenue or earnings guidance was provided; management cautioned that licensing revenue is uneven and difficult to predict.
- Acacia reported nine pending patent infringement cases with trial dates scheduled within six months. Trials, appeals, litigation costs, potential fee-shifting rules and possible sanctions or awards to defendants create uncertainty and could affect costs and revenue timing.
- Revenue was concentrated: two licensees provided 87% of Q3 revenue (60% and 27%); three accounted for 70% of nine-month revenue. Two licensees represented approximately 95% of period-end receivables.
- Acacia invested $10 million in a secured, convertible one-year Veritone loan bearing 6% interest and received warrants. The broader agreement contemplates up to $50 million of debt and equity investment, subject to conditions. The filing lists a contingent $10 million second loan and a $30 million Primary Warrant put right among contractual obligations.
- A $14.0 million cash deposit secures a guarantee related to enforcement of a German patent injunction; it is restricted and may remain so until the court matter is resolved. The guarantee automatically extends unless extinguished under German law.
- Disclosure controls were assessed as ineffective because of a material weakness involving accounting for infrequent, unusual or complex matters. A control failure involved stock-option accounting under ASC 718; management said the expense was properly reflected and expected to implement remediation in Q4 2016.
- After its October earnings release, Acacia completed the Veritone valuation and recorded $0.3 million of interest and loan accretion and $1.2 million of additional non-cash stock compensation. Q3 net income was adjusted from preliminary $8.0 million to $7.1 million and EPS from $0.16 to $0.14.
Key investor verification points
- Confirm collection of the $53.7 million receivables balance and settlement of related royalties and contingent legal fees payable, which totaled $25.0 million.
- Track revenue concentration, the durability of license-agreement economics, and whether limited patent intake constrains future licensing opportunities.
- Review subsequent impairment tests, litigation outcomes and costs, including the Adaptix portfolio write-off and German injunction-related guarantee.
- Monitor Veritone’s repayment, conversion and warrant terms, and any additional funding commitments or valuation changes.
- Assess remediation of the disclosed material weakness and whether disclosure controls become effective.